REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2021.03.30 | 07:15 | Permanent Information Releases / General Company News

puce Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) - HTML (w)

2021.03.23 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer - HTML (w)

2021.03.22 | 07:00 | Permanent Information Releases / Appointments

puce Novartis appoints Karen Hale as Chief Legal Officer - HTML (w)

2021.03.15 | 11:00 | Permanent Information Releases / General Company News

puce New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment - HTML (w)

2021.03.09 | 07:00 | Permanent Information Releases / General Company News

puce Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer - HTML (w)

2021.03.05 | 07:00 | Permanent Information Releases / General Company News

puce Novartis announces change to the Executive Committee - HTML (w)

2021.03.02 | 15:26 | Permanent Information Releases / General Company News

puce Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut - HTML (w)

2021.03.02 | 15:26 | Permanent Information Releases / General Company News

puce Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting - HTML (w)

2021.03.02 | 15:26 | Permanent Information Releases / General Company News

puce Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle - HTML (w)

2021.02.17 | 07:15 | Permanent Information Releases / General Company News

puce Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease - HTML (w)

2021.02.16 | 19:22 | Permanent Information Releases / General Company News

puce Novartis Entresto® granted expanded indication in chronic heart failure by FDA - HTML (w)

2021.02.11 | 13:00 | Permanent Information Releases / General Company News

puce Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics - HTML (w)

2021.01.29 | 18:05 | Permanent Information Releases / General Company News

puce Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis - HTML (w)

2021.01.26 | 07:00 | Permanent Information Releases / Sales and Revenues

puce En 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments - HTML (w)

2021.01.26 | 07:00 | Permanent Information Releases / General Company News

puce Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1400